INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CHOROIDAL NEVUS

被引:15
|
作者
Chiang, Allen [2 ]
Bianciotto, Carlos [1 ]
Maguire, Joseph I. [2 ]
Park, Carl H. [2 ]
Baker, Paul S. [2 ]
Shields, Jerry A. [1 ]
Shields, Carol L. [1 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Inst, Ocular Oncol Serv, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Wills Eye Inst, Retina Serv, Philadelphia, PA 19107 USA
关键词
choroid; nevus; choroidal neovascularization; hemorrhage; bevacizumab; avastin; 3422 CONSECUTIVE EYES; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; SECONDARY; AGE; GROWTH; VERTEPORFIN; MELANOMAS; AVASTIN; TUMORS;
D O I
10.1097/IAE.0b013e31822092b7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report 10 cases of occult choroidal neovascularization (CNV) associated with choroidal nevus managed with intravitreal bevacizumab. Methods: Interventional case series. Each nevus was examined and imaged with fluorescein angiography, B-scan ultrasonography, and optical coherence tomography. Data were retrospectively analyzed to evaluate outcomes of treatment response and visual acuity. Results: Nine patients presented with CNV overlying a chronic choroidal nevus with a posterior margin within 1.5 mm of the foveola. In the 10th patient, the posterior margin of the nevus was located 10 mm from the foveola with extension of subretinal fluid into the macula. The CNV was subfoveolar in four cases, juxtafoveolar in two cases, and extrafoveolar in four cases. Initial visual acuity was 20/20 to 20/50 in 5, 20/60 to 20/100 in 2, and 20/200 or worse in 3 cases. Clinical features included subfoveolar fluid in nine, exudation in five, and hemorrhage in four cases. Intravitreal bevacizumab (1.25 mg/0.05 cc) was injected with regression of CNV in all 10 cases using 2 to 14 injections (median 3 injections). In 2 eyes, after therapeutic response to bevacizumab later consolidation with photodynamic therapy (juxtafoveolar CNV) (n = 1) or conventional laser (extrafoveolar CNV) (n = 1) was provided. In the remaining 8 eyes, after discontinuation of bevacizumab, there was no recurrence of CNV over mean 10.1 months. At overall mean follow-up of 22.5 months, final visual acuity decreased by 1 line in 4 cases and improved by mean of 3 lines (range, 1-8 lines) in 6 cases. There were no adverse effects from bevacizumab injections. All 10 choroidal nevi remained stable. Conclusion: Intravitreal bevacizumab appears to be an effective treatment option for CNV secondary to choroidal nevus. In some cases, depending on the proximity of the CNV to the foveola, photodynamic therapy or conventional laser may be useful adjunctive therapy. RETINA 32:60-67, 2012
引用
收藏
页码:60 / 67
页数:8
相关论文
共 50 条
  • [21] Treatment of peripapillary choroidal neovascularization with intravitreal bevacizumab
    Hoeh, A. E.
    Schaal, K. B.
    Ach, T.
    Dithmar, S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2009, 19 (01) : 163 - 165
  • [22] Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization
    Mandal, Subrata
    Garg, Satpal
    Venkatesh, Pradeep
    Mithal, Charu
    Vohra, Rajpal
    Mehrotra, Abhas
    ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (11) : 1487 - 1492
  • [23] Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to traumatic choroidal rupture
    Chanana, B.
    Azad, R. V.
    Kumar, N.
    EYE, 2009, 23 (11) : 2125 - 2126
  • [24] Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation
    Wolf, Armin
    Thurau, Stephan
    Kook, Daniel
    Hoeing, Anna
    Priglinger, Siegfried
    Kampik, Anselm
    Haritoglou, Christos
    ACTA OPHTHALMOLOGICA, 2010, 88 (07) : e295 - e296
  • [25] Treatment of choroidal neovascularization using intravitreal bevacizumab
    Pedersen, Robert
    Soliman, Wael
    Lund-Andersen, Henrik
    Larsen, Michael
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2007, 85 (05): : 526 - 533
  • [26] Choroidal neovascularization in children treated by intravitreal bevacizumab
    Smailhodzic, D.
    Tjon-Fo-Sang, M.
    Poels, M. F.
    Ossewaarde-Van Norel, J.
    van Genderen, M. M.
    van den Born, L. I.
    ACTA OPHTHALMOLOGICA, 2023, 101 : 31 - 31
  • [27] Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis
    Schadlu, Ramin
    Blinder, Kevin J.
    Shah, Gaurav K.
    Holekamp, Nancy M.
    Thomas, Matthew A.
    Grand, M. Gilbert
    Engelbrecht, Nicholas E.
    Apte, Rajendra S.
    Joseph, Daniel P.
    Prasad, Anita G.
    Smith, Bradley T.
    Sheybani, Arsham
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (05) : 875 - 878
  • [28] Intravitreal bevacizumab for posttraumatic choroidal neovascularization in a child
    Piermarocchi, Stefano
    Benetti, Elisa
    Fracasso, Gianfranco
    JOURNAL OF AAPOS, 2011, 15 (03): : 314 - 316
  • [29] Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to traumatic choroidal rupture
    B Chanana
    R V Azad
    N Kumar
    Eye, 2009, 23 : 2125 - 2126
  • [30] Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma
    Yoshikawa, Tadanobu
    Takahashi, Kanji
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 429 - 437